Omeprazol Serraclinics (Omeprazole Sodium)

Omeprazole Sodium, the active ingredient in Omeprazol Serraclinics, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults and children.

GNH USA supplies Omeprazol Serraclinics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as adjunct therapy to improve eradication rates. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in high‑risk patients.

Adverse reactions reported with omeprazole vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or vomiting: transient gastrointestinal upset. - Abdominal pain or flatulence: mild discomfort. - Constipation: occasional bowel habit change. - Dry mouth: reduced salivary flow.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, airway compromise. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, arrhythmia risk. - Bone fractures: increased risk with long‑term use. - Vitamin B12 deficiency: anemia, neuropathy with prolonged therapy. - Acute interstitial nephritis: renal impairment signs.

When prescribing omeprazole, consider the following safety measures: - Assess renal and hepatic function: dose adjustment may be required in impairment. - Review concomitant medications: potential for drug‑drug interactions. - Evaluate need for long‑term therapy: weigh benefits against fracture and infection risk. - Monitor electrolytes: especially magnesium during extended use. - Counsel patients on symptom monitoring: report severe abdominal pain or persistent diarrhea. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir or other protease inhibitors: markedly decreased antiviral exposure. - Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, require more frequent monitoring. - Digoxin: modest increase in serum levels, watch for toxicity signs. - Phenytoin: reduced clearance, may need dose adjustment. - Iron supplements: decreased absorption, separate dosing times. - Ketoconazole or other azole antifungals: reduced absorption, consider alternative agents.